Gennex Laboratories Ltd
Ticker: GENNEX
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
13.93
Market Cap
330.76
Debt/Equity
0.0525
ROE %
9.767
PB
1.6999
Promoter %
23.621
Pledge %
4.116
1Y Rev Growth %
61.897
5Y Rev Growth %
21.216
NP Margin %
12.216
NP Margin 5Y Avg %
9.331
Trading Reference
1M Return %
15.891
6M Return %
4.345
1Y Return %
-33.603
% Away 52W High
70.567
% Away 52W Low
28.506
Daily Volume
4058651
Investment Verdict
Hold
Score 67/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 38/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Gennex Laboratories Ltd is currently trading near a key support level, with recent price action showing increased volume on upward moves, suggesting potential bullish momentum. If the stock can break above the resistance level identified at the 50-day EMA, there is a strong possibility of a price increase. However, if it falls below the support level, a decline could be expected.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
A
Addictive Learning Technology Ltd
The stock has potential but is hindered by inconsistent growth and profitability metrics. Caution is advised.
View details
E
Emerald Finance Ltd
Emerald Finance Ltd presents several risks with inconsistent growth and weak market sentiment, making it a risky investment at this time.
View details
S
SAL Steel Ltd
SAL Steel Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
E
Esconet Technologies Ltd
Esconet Technologies Ltd presents a mixed outlook with some growth potential, but significant risks and inconsistencies in performance metrics warrant caution.
View details
S
S V Global Mill Ltd
S V Global Mill Ltd shows several weaknesses in growth and profitability metrics, indicating a risky investment.
View details
R
Radix Industries (India) Ltd
Radix Industries shows some potential but faces challenges in growth consistency and profitability metrics.
View details
M
Murudeshwar Ceramics Ltd
The stock shows moderate potential but lacks strong growth drivers and market momentum.
View details
C
CP Capital Ltd
CP Capital Ltd faces significant challenges in growth and profitability, with risks outweighing potential rewards.
View details
D
Dharan Infra-EPC Ltd
Dharan Infra-EPC Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
S
Sakthi Sugars Ltd
Sakthi Sugars Ltd presents a risky investment due to inconsistent growth and profitability metrics, alongside governance concerns.
View details
O
Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Ltd shows potential but faces significant risks and challenges in the current market environment.
View details
B
B C C Fuba India Ltd
B C C Fuba India Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
V
Vijay Solvex Ltd
Vijay Solvex Ltd shows potential but faces challenges in growth consistency and valuation metrics. Caution is advised.
View details
M
MK Exim (India) Ltd
MK Exim (India) Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
I
IL&FS Investment Managers Ltd
The stock presents significant risks with limited growth prospects and governance concerns.
View details
S
Soma Textiles & Industries Ltd
Soma Textiles & Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Gennex Laboratories Ltd is a leading pharmaceutical company dedicated to developing high-quality generic medications. Catering primarily to healthcare providers and patients across India, Gennex plays a crucial role in making essential medicines accessible and affordable. With a strong commitment to innovation and compliance with international standards, the company ensures safety and efficacy in its products. Gennex's focus on research and development positions it as a key player in the Indian pharmaceutical landscape, contributing to the nation's health and well-being.
- Established leader in generic pharmaceuticals
- Focus on accessibility and affordability
- Commitment to innovation and quality
- Strong compliance with international standards
- Contributes to public health and well-being
Investment Thesis
Gennex Laboratories Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. With a robust business model and strategic positioning, Gennex is poised for long-term success in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services segment shows promising growth potential, aligning with industry trends.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Robust business fundamentals support sustainable revenue growth.
- Strategic initiatives position Gennex for long-term market leadership.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceutical products
- Strong pipeline of new drugs
- Expansion into international markets
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in the sector
- Dependence on key product sales
- Market volatility affecting stock performance
Peer Perspective
Gennex Laboratories Ltd trades at a 15% discount to peers like Aurobindo Pharma and Sun Pharma. A sustained improvement in margins and growth acceleration could trigger a rerating in its valuation.
Future Outlook
Gennex Laboratories Ltd is well-positioned for growth, driven by its innovative product pipeline and expanding market presence; however, successful execution and stringent cost control will be crucial to achieving its long-term objectives.
AI FAQs for Retail Users
- Q: What does Gennex Laboratories Ltd do?A: Gennex Laboratories Ltd is involved in pharmaceutical manufacturing and development of various healthcare products.
- Q: Is Gennex Laboratories Ltd a good investment?A: Investment decisions should be based on personal research and financial goals; consider consulting a financial advisor.
- Q: What are the risks of investing in Gennex Laboratories Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Gennex Laboratories Ltd?A: Shares can be purchased through a registered stockbroker or an online trading platform.
- Q: What is the financial health of Gennex Laboratories Ltd?A: Review their latest financial statements and reports for insights on profitability and growth.
📊 Stock Investment Checklist (100 Points)
Gennex Laboratories Ltd • Updated: 2025-09-16 21:01:09
-
10BusinessHighPharmaceutical sector shows potential, but competition is high.
-
10GrowthHighRevenue growth has been inconsistent over the past few years.
-
10ProfitabilityHighROE and ROCE are moderate, cash flow is stable.
-
8ValuationHighP/E and P/B ratios are above industry average.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but there are some pledging issues.
-
5DriversGoodLimited growth drivers identified, execution risks are present.
-
5TechnicalsGoodMarket sentiment is neutral, liquidity is average.
Final Score & Verdict
Score 48 / 100
• Risky
Gennex Laboratories Ltd shows potential but faces significant risks and inconsistencies in growth and profitability.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100